BAD and cancer: Hence, as a common downstream cell survival mediator of both the RAS/RAF/MAPK and PI3K/AKT/mTPR pathways, phosphorylated BAD has been demonstrated to be critically involved in cancer development, progression, and therapeutic resistance.